Granted Patent
B2
US 12,398,204 · App. 18/528,957 · Granted Aug 26, 2025
Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonist
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with angiogenesis, comprising administering a multi-specific compound that targets a phosphatase and a receptor tyrosine kinase agonist.
Claims (21)
1. A method of treating an ocular condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antibody comprising:
(a) a first domain that activates Tie2, wherein the first domain comprises an amino acid sequence that is any one of SEQ ID NOs: 76-80, an amino acid sequence that is any one of SEQ ID NOs: 81-87, an amino acid sequence that is any one of SEQ ID NOs: 88-90, an amino acid sequence that is any one of SEQ ID NOs: 91-93, an amino acid sequence that is any one of SEQ ID NOs: 94-96, and an amino acid sequence that is any one of SEQ ID NOs: 97-98; and
(b) a second domain that specifically binds a receptor tyrosine kinase agonist, wherein the second domain comprises an amino acid sequence that is any one of SEQ ID NOs: 99-113, an amino acid sequence that is any one of SEQ ID NOs: 114-123, an amino acid sequence that is any one of SEQ ID NOs: 124-131, an amino acid sequence that is any one of SEQ ID NOs: 132-137, an amino acid sequence that is any one of SEQ ID NOs: 138-143, and an amino acid sequence that is any one of SEQ ID NOs: 144-146.
2. The method of claim 1 , wherein the ocular condition is diabetic retinopathy.
3. The method of claim 1 , wherein the ocular condition is neovascularization.
4. The method of claim 1 , wherein the ocular condition is vascular leak.
5. The method of claim 1 , wherein the ocular condition is increased intraocular pressure.
6. The method of claim 1 , wherein the ocular condition is ocular edema.
7. The method of claim 1 , wherein the ocular condition is diabetic macular edema.
8. The method of claim 1 , wherein the ocular condition is wet age-related macular degeneration.
9. The method of claim 1 wherein the ocular condition is ocular inflammation.
10. The method of claim 1 , wherein the ocular condition is retinal vein occlusion.
11. The method of claim 1 , wherein the administering is to an eye of the subject.
12. The method of claim 1 , wherein the administering is intravitreal.
13. The method of claim 1 , wherein the administering is subcutaneous.
14. The method of claim 1 , wherein the subject is a human.
15. The method of claim 1 , wherein the therapeutically effective amount is from about 0.25 mg to about 200 mg.
16. The method of claim 1 , wherein the therapeutically effective amount is from about 1 mg/kg to about 10 mg/kg.
17. The method of claim 1 , wherein the antibody inhibits HPTP-β.
18. The method of claim 1 , wherein the antibody inhibits VE-PTP.
19. The method of claim 1 , wherein the antibody inhibits VEGF.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 9, 2025
From: PETERS, KEVIN
To: AERPIO PHARMACEUTICALS, INC.
Reel/Frame 069796/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 9, 2025
From: AERPIO PHARMACEUTICALS, INC.
To: EYEPOINT PHARMACEUTICALS, INC.
Reel/Frame 069855/0889 →
Continuity (5)
Provisional Application
62832461
· Apr 11, 2019
Provisional Application
62735331
· Sep 24, 2018
References Cited (280)
US 4179337A
· Davis et al.
· 1979
[cited by applicant]
US 4301144A
· Iwasaki et al.
· 1981
[cited by applicant]
US 4496689A
· Mitra
· 1985
[cited by applicant]
US 4640835A
· Shimizu et al.
· 1987
[cited by applicant]
US 4670417A
· Iwasaki et al.
· 1987
[cited by applicant]
US 4791192A
· Nakagawa et al.
· 1988
[cited by applicant]
US 5625825A
· Rostoker et al.
· 1997
[cited by applicant]
US 6133426A
· Gonzalez et al.
· 2000
[cited by applicant]
US 6407213B1
· Carter et al.
· 2002
[cited by applicant]
US 7226755B1
· Peters et al.
· 2007
[cited by applicant]
US 7374758B2
· Papadopoulos et al.
· 2008
[cited by applicant]
US 7758859B2
· Fuh et al.
· 2010
[cited by applicant]
US 7973142B2
· Rotello et al.
· 2011
[cited by applicant]
US 8258268B2
· Wu et al.
· 2012
[cited by applicant]
US 8268314B2
· Baehner et al.
· 2012
[cited by applicant]
US 8349322B2
· Borras et al.
· 2013
[cited by applicant]
US 8524235B2
· Rotello et al.
· 2013
[cited by applicant]
US 8901076B2
· Binz et al.
· 2014
[cited by applicant]
US 8999325B2
· Peters et al.
· 2015
[cited by applicant]
US 9174950B2
· Shalwitz et al.
· 2015
[cited by applicant]
US 9403789B2
· Eissenstat et al.
· 2016
[cited by applicant]
US 9458211B1
· Bakker et al.
· 2016
[cited by applicant]
US RE46592E
· Gray et al.
· 2017
[cited by applicant]
US 9795594B2
· Gray et al.
· 2017
[cited by applicant]
US 9926367B2
· Rotello et al.
· 2018
[cited by applicant]
US 9968674B2
· Ioffe et al.
· 2018
[cited by applicant]
US 20030158083A1
· Peters
· 2003
[cited by applicant]
US 20030215899A1
· Meng et al.
· 2003
[cited by applicant]
US 20040077065A1
· Evdokimov et al.
· 2004
[cited by applicant]
US 20040254197A1
· Tasaka et al.
· 2004
[cited by applicant]
US 20050059639A1
· Wei
· 2005
[cited by applicant]
US 20070134234A1
· Smith et al.
· 2007
[cited by applicant]
US 20070154482A1
· Sukhatme et al.
· 2007
[cited by applicant]
US 20070299116A1
· Gray et al.
· 2007
[cited by applicant]
US 20080004267A1
· Gray et al.
· 2008
[cited by applicant]
US 20080108631A1
· Gray et al.
· 2008
[cited by applicant]
US 20090022715A1
· Rotello et al.
· 2009
[cited by applicant]
US 20090227639A1
· Gray et al.
· 2009
[cited by applicant]
US 20090246206A1
· Nielsen et al.
· 2009
[cited by applicant]
US 20100030487A1
· Evdokimov et al.
· 2010
[cited by applicant]
US 20100069448A1
· Gray et al.
· 2010
[cited by applicant]
US 20100111894A1
· Benny-Ratsaby et al.
· 2010
[cited by applicant]
US 20100256147A1
· Hangauer
· 2010
[cited by applicant]
US 20110212951A1
· Gray et al.
· 2011
[cited by applicant]
US 20110268656A1
· Ho et al.
· 2011
[cited by applicant]
US 20110268694A1
· Shalwitz et al.
· 2011
[cited by applicant]
US 20110274699A1
· Rotello et al.
· 2011
[cited by applicant]
US 20120077853A1
· Gray et al.
· 2012
[cited by applicant]
US 20120077975A1
· Gray et al.
· 2012
[cited by applicant]
US 20120128625A1
· Shalwitz et al.
· 2012
[cited by applicant]
US 20120129847A1
· Peters et al.
· 2012
[cited by applicant]
US 20120237442A1
· Rossi et al.
· 2012
[cited by applicant]
US 20130023543A1
· Gray et al.
· 2013
[cited by applicant]
US 20130095105A1
· Peters et al.
· 2013
[cited by applicant]
US 20130096140A1
· Gray et al.
· 2013
[cited by applicant]
US 20130324558A1
· Gray et al.
· 2013
[cited by applicant]
US 20140179693A1
· Shalwitz et al.
· 2014
[cited by applicant]
US 20140221666A1
· Gray et al.
· 2014
[cited by applicant]
US 20140242026A1
· Shalwitz et al.
· 2014
[cited by applicant]
US 20140249100A1
· Shalwitz et al.
· 2014
[cited by applicant]
US 20140275103A1
· Peters et al.
· 2014
[cited by applicant]
US 20150065781A1
· Bais et al.
· 2015
[cited by applicant]
US 20150210656A1
· Gray et al.
· 2015
[cited by applicant]
US 20150297675A1
· Osborne
· 2015
[cited by applicant]
US 20160008327A1
· Shalwitz et al.
· 2016
[cited by applicant]
US 20160030393A1
· Breslin et al.
· 2016
[cited by applicant]
US 20160038467A1
· Peters
· 2016
[cited by applicant]
US 20160075797A1
· Weaver et al.
· 2016
[cited by applicant]
US 20160082129A1
· Peters
· 2016
[cited by applicant]
US 20160130337A1
· Gekkieva et al.
· 2016
[cited by applicant]
US 20160251421A1
· Brown et al.
· 2016
[cited by applicant]
US 20160333090A1
· Horlick et al.
· 2016
[cited by applicant]
US 20160340420A1
· Zhang et al.
· 2016
[cited by applicant]
US 20170096479A1
· Koenig et al.
· 2017
[cited by applicant]
US 20170260265A1
· Duerr et al.
· 2017
[cited by applicant]
US 20170275353A1
· Sheng et al.
· 2017
[cited by applicant]
US 20170298019A1
· Gardner et al.
· 2017
[cited by applicant]
US 20170319602A1
· Peters et al.
· 2017
[cited by applicant]
US 20170349649A1
· Rotello et al.
· 2017
[cited by applicant]
US 20180009890A1
· Peters et al.
· 2018
[cited by applicant]
US 20180022741A1
· Peters et al.
· 2018
[cited by applicant]
US 20180022804A1
· Peters et al.
· 2018
[cited by applicant]
US 20180037579A1
· Peters et al.
· 2018
[cited by applicant]
US 20180044432A1
· Peters et al.
· 2018
[cited by applicant]
US 20180092883A1
· Peters et al.
· 2018
[cited by applicant]
US 20180207233A1
· Rudolf et al.
· 2018
[cited by applicant]
US 20180221346A1
· Gray et al.
· 2018
[cited by applicant]
US 20180237429A1
· Peters et al.
· 2018
[cited by applicant]
US 20180237430A1
· Peters et al.
· 2018
[cited by applicant]
US 20180251457A1
· Peters et al.
· 2018
[cited by applicant]
US 20180353614A1
· Peters
· 2018
[cited by applicant]
US 20190023773A1
· Rotello et al.
· 2019
[cited by applicant]
US 20190046609A1
· Yancopoulos
· 2019
[cited by applicant]
US 20190076405A1
· Shalwitz
· 2019
[cited by applicant]
US 20190077862A1
· Peters et al.
· 2019
[cited by applicant]
US 20190077863A1
· Peters et al.
· 2019
[cited by applicant]
US 20190218282A1
· Dengl et al.
· 2019
[cited by applicant]
US 20190256889A1
· Quaggin
· 2019
[cited by applicant]
US 20190290725A1
· Vitti et al.
· 2019
[cited by applicant]
US 20190343918A1
· Graham et al.
· 2019
[cited by applicant]
US 20190381008A1
· Zeitz et al.
· 2019
[cited by applicant]
US 20200087412A1
· Fang et al.
· 2020
[cited by applicant]
US 20200115455A1
· Bedi et al.
· 2020
[cited by applicant]
US 20200140547A1
· Bedi et al.
· 2020
[cited by applicant]
US 20200231703A1
· Peters et al.
· 2020
[cited by applicant]
US 20210095017A1
· Peters et al.
· 2021
[cited by applicant]
US 20210171618A1
· Peters
· 2021
[cited by applicant]
US 20230134885A1
· Peters et al.
· 2023
[cited by applicant]
CN 101802002A
· 2010
[cited by applicant]
CN 102753577A
· 2012
[cited by applicant]
CN 107602702A
· 2018
[cited by applicant]
EP 2592073B1
· 2017
[cited by applicant]
EP 2846836B1
· 2019
[cited by applicant]
EP 3628324A1
· 2020
[cited by applicant]
WO WO9312227A1
· 1993
[cited by applicant]
WO WO9631598A1
· 1996
[cited by applicant]
WO WO9845331A3
· 1998
[cited by applicant]
WO WO0224782A1
· 2002
[cited by applicant]
WO WO2007033216A2
· 2007
[cited by applicant]
WO WO2007087457A2
· 2007
[cited by applicant]
WO WO2007116360A2
· 2007
[cited by applicant]
WO WO2008132568A2
· 2008
[cited by applicant]
WO WO2009006112A1
· 2009
[cited by applicant]
WO WO2009055343A2
· 2009
[cited by applicant]
WO WO2009136352A1
· 2009
[cited by applicant]
WO WO2010040508A1
· 2010
[cited by applicant]
WO WO2010060748A1
· 2010
[cited by applicant]
WO WO2011135067A1
· 2011
[cited by applicant]
WO WO2013056233A1
· 2013
[cited by applicant]
WO WO2013056240A1
· 2013
[cited by applicant]
WO WO2011087066A1
· 2013
[cited by applicant]
WO WO2015109898A1
· 2015
[cited by applicant]
WO WO2016049183A1
· 2016
[cited by applicant]
WO WO2016115092A1
· 2016
[cited by applicant]
WO WO2016122996A1
· 2016
[cited by applicant]
WO WO2017035430A2
· 2017
[cited by applicant]
WO WO2018017714A1
· 2018
[cited by applicant]
WO WO2018067646A1
· 2018
[cited by applicant]
WO WO2018229034A1
· 2018
[cited by applicant]
WO WO2019168947A1
· 2019
[cited by applicant]
WO WO2019175727A1
· 2019
[cited by applicant]
WO WO2019222547A1
· 2019
[cited by applicant]
WO WO2020068653A1
· 2020
[cited by applicant]
Attwood. Genomics. The Babel of bioinformatics. Science. Oct. 20, 2000;290(5491):471-3.
[cited by applicant]
Campbell. Chapter 1: General properties and applications of monoclonal antibodies. Monoclonal Antibody Technology. Elsevier Science Publishers, The Netherlands, (pp. 1-32) (1984).
[cited by applicant]
Clarke, JM et al., Targeted inhibition of VEGF Receptor-2: An update on Ramucirumab, Expert Opin Biol. Ther. Aug. 2013 ; 13(8): 1187-1196. doi:10.1517/14712598.2013.810717.
[cited by applicant]
Colman et al., Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology, 1994; 145(1):33-36.
[cited by applicant]
Crescioli, Silvia et al., IgG4 Characteristics and Functions in Cancer Immunity, Curr Allerty Asthma Rep (2016) 16:7.
[cited by applicant]
Goel, et al. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst. Aug. 21, 2013; 105(16):1188-201. doi: 10.1093/jnci/djt164…
[cited by applicant]
Golay, et al. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys. Oct. 15, 2012;526(2):146-53. doi: 10.1016/j.abb.2012.02.011. Epub Feb. …
[cited by applicant]
Houghten, et al. New Approaches to Immunization, Vaccines 86, Cold Spring Harbor Laboratory, p. 21-25, 1986.
[cited by applicant]
International Search Report and Written Opinion dated Feb. 5, 2020, for PCT/US19/52405.
[cited by applicant]
International Union of Basic and Clinical Pharmacology (IUPHAR) /British Pharmacological Society (BPS) Guide to Pharmacology Database: Ligand ID: 8371, International Non-proprietary Name: abicipar pegol, Synonyms: AGN-1…
[cited by applicant]
International Union of Basic and Clinical Pharmacology (IUPHAR) /British Pharmacological Society (BPS) Guideto Pharmacology Database: Ligand ID: 8371, International Non-proprietary Name: abicipar pegol, Biological activ…
[cited by applicant]
International Union of Basic and Clinical Pharmacology (IUPHAR)/British Pharmacological Society (BPS) Guideto Pharmacology Database: Ligand ID: 8371, International Non-proprietary Name: abiciparpegol, Target: VEGFA, pri…
[cited by applicant]
International Union of Basic andClinical Pharmacology (IUPHAR) /British Pharmacological Society (BPS)Guideto Pharmacology Database: Ligand ID: 8371, Intl Non-proprietary Name: abicipar pegol, Clinical Data; Summary of C…
[cited by applicant]
IUPHAR/BPS Guide to Pharmacology database for Ligand ID: 8371, Name: abicipar pegol, available at https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=8371 , 5 pages, Printed Nov. 21, 2…
[cited by applicant]
Kienast, Y. et al., Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent antitumor, Antiangiogenic, and Antimetastic Efficascy, Clinical Cance…
[cited by applicant]
Nguyen, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. Dec. 2006;142(6):961-9. Epub Aug. 2, 2006.
[cited by applicant]
Owens, et al. The genetic engineering of monoclonal antibodies. J Immunol Methods. Feb. 10, 1994;168(2):149-65.
[cited by applicant]
Paul. Fundamental Immunology. Chapter 8 Immunogenicty and antigen structure., 3d ed., p. 242, 1993.
[cited by applicant]
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. PNAS USA 79:1979-1983 (1982).
[cited by applicant]
Shen, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. Oct. 2014;124(10):4564-76.
[cited by applicant]
Silva, Raquel Lima et al., Tyrosine blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage, Sci Transl Med. Jan. 18, 2017; 9(373). doi:10.1126/scitranslmed.aai8030.
[cited by applicant]
Simeon, Rudo et al., In vitro-engineered non-antibody protein therapeutics, Protein Cell 218, 9(1);3-14.
[cited by applicant]
Skolnick, et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. Jan. 2000;18(1):34-9.
[cited by applicant]
Tam, Susan H. et al., Functional Biophysical, and Structural Characterization of Human IgG1 and Ig4Fc Variants with Ablated Immune Functionality, Antibodies 2017, 6 12: doi:10.3390/antib6030012.
[cited by applicant]
Trieu, Michelle et al., Vasculotide, an Angiopoietin-1, Mimetic, Restores Microcirculatory Perfusion and Microvascular Leakage and Decreases Fluid Resuscitation Requirements in Hemorrhagic Shock, Anesthesiology, V. 128,…
[cited by applicant]
Van Der Flier, et al. Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. J Neuroimmunol. Mar. 2005;160(…
[cited by applicant]
Wang, Qin, et al., Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGR Isoforms Provide Remarkable Anti-Angiogenesis Effect in Viv, Aug. 2013: PLOS One, vol. 8, Issue 8.
[cited by applicant]
Wang, Xinhua et al., IgG engineering to modulate antibody effector functions, Genetech,Protein Cell 2018; 9(1:)63-73; DOI 10.107/sAcceptd Jun. 19, 2017.
[cited by applicant]
Witte, et al. Monoclonal antibodies targeting the VEGF receptor-2 (FIk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. Jun. 1998;17(2):155-61.
[cited by applicant]
Wu et al. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J.Mol.Biol. 294:151-162 (1999).
[cited by applicant]
Yang, Jihong et al., Comparison of Binding Characteristics and In Vitro Activities of Three Inhibitors of Vascular Endothelial Grow Factor A, Molecular Pharmaceutics, 2014, American Chemical Society, 3421-3430.
[cited by applicant]
Yu et al., Interaction between Bevacizumab and Murine VEGF-A: A Reassessment, Investigative Ophthalmology & Visual Science, 2008, vol. 49 (2), pp. 522-527.
[cited by applicant]
Amarasinghe, K.K.D., et al., “Design and synthesis of potent, non-peptidic inhibitors of HPTPß,” Bioorganic & Medicinal Chemistry Letters, 16:4252-4256, Elsevier, Netherlands (2006).
[cited by applicant]
Baumer, S., et al., “Vascular endothelial cell-specific phosphotyrosine phosphatase (VEPTP) activity is required for blood vessel development,” Blood 107(12):4754-4762, The American Society of Hematology, United States …
[cited by applicant]
Bosse, R. and Vestweber D., “Only simultaneous blocking of the L- and P-selectin completely inhibits neutrophil C migration into mouse peritoneum”, Eur. J. Immunol. 24:3019-3024, VCH Verlagsgesellschaft mbH, Germany (19…
[cited by applicant]
Broermann, A., et al., “Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo,” J Exp Med. 208(12):2393-401, The Rockefeller University Press,…
[cited by applicant]
Campbell,A.M., “Monoclonal Antibody Technology,” Chapter 1, pp. 1-32, Elsevier, Inc., Netherlands (1984).
[cited by applicant]
Campochiaro, P.A., et al., “Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression. Ophthalmology,” 123(8):1-9, Elsevier, Inc., Netherlands …
[cited by applicant]
Clackson, T., et al., “Making antibody fragments using phage display libraries,” Nature. 352(6336):624-628, Nature Research, United Kingdom (Aug. 1991).
[cited by applicant]
Doukas, J., et al., “Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema,” J Cell Physiol. 216(1):29-37, Author Manuscript, John Wiley & Sons, Inc., Unit…
[cited by applicant]
Edwards, B.M., et al., “The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS,” J Mol Biol 334(1):103-18, Elsevier, Netherlands (Nov. …
[cited by applicant]
Elias, L. and Hunt, W.C., “A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy,” Oncology 61(2):91-101, S. Karger AG, Bas…
[cited by applicant]
Frye, M., et al., “Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence ofVE-cadherin,” JEM 212(13):2267-2287, The Rockefeller University Press, United States (Dec. 2015).
[cited by applicant]
Fukuhara, S. and Mochizuki, N., “Vascular endothelial cells and adjoining cells for their mutual adhesion/interaction for stabilization and angiogenesis,” Seikagaku. The Journal of Japanese Biochemical Society 82(4):290…
[cited by applicant]
Fukuhara, S., et al., “Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1,” Nat Cell Biol. 10(5):513-526, Nature Publishing Group, Germany (May 2008).
[cited by applicant]
Gallagher, D.C., et al., “Angiopoietin 2 is a Potential Mediator of High-Dose Interleutkin 2-Induced Vascular Leak,” Clin Cancer Res 13(7):2115-2120, American Association for Cancer Research, United States (Apr. 2007).
[cited by applicant]
Gotsch, U., et al., “VE-cadherin antibody accelerates neutrophil recruitment in vivo,” J Cell Sci. 110:583-588, The Company of Biologists Limited, Great Britain (Mar. 1997).
[cited by applicant]
Gozes, Y., et al., “Anthrax Lethal Toxin Induces Ketotifen-Sensitive Intradermal Vascular Leakage in Certain Inbred Mice,” Infect Immun. 74(2):1266-1272, The American Society for Microbiology, United States (Feb. 2006).
[cited by applicant]
Gurnik, S., et al., “Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling,” Acta Neuropathol 131(5):753-773, Springer, Germany (Ma…
[cited by applicant]
Hayashi, M., et al., VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat Commun. 4:1672, Macmillan Publishing Limited, United Kingdom (2013).
[cited by applicant]
Hudson, P.J. and Souriau, C., “Engineered antibodies,” Nat Med. 9(1):129-34, Nature Publishing Group, Germany (Jan. 2003).
[cited by applicant]
Imamura, T., et al., “Induction of vascular leakage through release of bradykinin and a novel kin in by cysteine proteinases from
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2012/060263, U.S. Patent and Trademark Office, Alexandria, VA, mailed on Dec. 6, 2012, 7 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2012/060273, U.S. Patent and Trademark Office, Alexandria, VA, mailed on Dec. 24, 2012, 9 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/042855, U.S. Patent and Trademark Office, Alexandria, VA, mailed on Dec. 26, 2017, 21 pages.
[cited by applicant]
Jubala, C.M., et al., “CD20 expression in normal canine B cells and in canine non-Hodgkin Lymphoma,” Vet Pathol. 42(4):468-476, SAGE Publications, New York (Jul. 2005).
[cited by applicant]
Kipriyanov, S.M. and Le Gall, F., “Generation and production of engineered antibodies,” Mol Biotechnol. 26(1):39-60, Humana Press, Inc., Springer Science+Business Media, Germany (Jan. 2004).
[cited by applicant]
Lloyd, C., et al., “Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engineering, Design & Selection 22:159-168, O…
[cited by applicant]
Lo, B.K.C., “Antibody humanization by CDR grafting,” Ch.7 in Methods in Mol Biol., Antibody Engineering: Methods and Protocols 248:135-59, Totowa, New Jersey (2004).
[cited by applicant]
Lucentis prescribing information, p. 1-28, Genentech, Inc. (2018).
[cited by applicant]
Luo, G., et al., “Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus,” J Virol. 71(5):4062-4070, American Society for Microbiology, United States (May 1997).
[cited by applicant]
Marneros, A., et al., “Endogenous endostatin inhibits choroidal neovascularization,” FASEB J. 21(14):3809-3818, Federation of American Societies for Experimental Biology, United States (Dec. 2007).
[cited by applicant]
Medicago AB phosphate-buffer saline specification sheet, p. 1-2, www.medicago.se (2010).
[cited by applicant]
Mellberg, S., et al., “Transcriptional profiling reveals a critical role for tyrosine phosphatase VEPTP in regulation of VEGFR2 activity and endothelial cell morphogenesis,” FASEB J. 23(5):1490-1502, Federation of Ameri…
[cited by applicant]
Miles, A.A. and Miles, E.M., “Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs,” J Physiol. 118(2):228-257, Wiley-Blackwell on behalf of The Physiological Society, United S…
[cited by applicant]
Morrissey, C., et al., “Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases,” Clin Exp Metastasis. 25(4):377-388, Springer Science+Business Media B.V., Germa…
[cited by applicant]
Muyldermans, S., “Single domain camel antibodies: current status,” Reviews in Molecular Biotechnology 74(4):277-302, Elsevier, Netherlands (Jun. 2001).
[cited by applicant]
Nishimura, E., “Current status and feature of diabetic retinopathy drug therapy,” Journal of the Showa Medical Association 70(1):45-51, Showa Medical Association, Japan (Feb. 2010).
[cited by applicant]
Notice of Allowance dated Jan. 15, 2020, in U.S. Appl. No. 16/180,850, Peters, K., filed Nov. 5, 2018, 9 pages.
[cited by applicant]
Notice of Allowance mailed Jan. 30, 2015, in U.S. Appl. No. 13/652,154, Peters, K., filed Oct. 15, 2012, 8 pages.
[cited by applicant]
Notice of Allowance mailed Nov. 30, 2018, in U.S. Appl. No. 15/654,289, Peters, K., filed Jul. 19, 2017, 7 pages.
[cited by applicant]
Notice of Allowance mailed Sep. 26, 2018, in U.S. Appl. No. 15/438,218, Peters, K., filed Feb. 21, 2017, 8 pages.
[cited by applicant]
Nottebaum, A.F., et al. VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF, J Exp Med. 205(12):2929-2945, The Rockefeller University Press, United…
[cited by applicant]
Office Action mailed Apr. 17, 2015, in U.S. Appl. No. 13/652,203, Peters, K., et al., filed Oct. 15, 2012, 12 pages.
[cited by applicant]
Office Action mailed Apr. 7, 2014, in U.S. Appl. No. 13/652,154, Peters, K., et al., filed Oct. 15, 2012, 25 pages.
[cited by applicant]
Office Action mailed Aug. 22, 2016 in U.S. Appl. No. 13/652,203, Peters, K., et al., filed Oct. 15, 2012, 15 pages.
[cited by applicant]
Office Action mailed Aug. 3, 2018, in U.S. Appl. No. 15/438,218, Peters, K., et al., filed Feb. 21, 2017, 8 pages.
[cited by applicant]
Office Action mailed Aug. 30, 2019, in U.S. Appl. No. 16/180,850, Peters, K., et al., filed Nov. 5, 2018, 11 pages.
[cited by applicant]
Office Action mailed Aug. 30, 2019, in U.S. Appl. No. 16/180,854, Peters, K., et al., filed Nov. 5, 2018, 11 pages.
[cited by applicant]
Office Action mailed Jan. 4, 2016, in United States U.S. Appl. No. 13/652,203, Peters, K., et al., filed Oct. 15, 2012, 17 pages.
[cited by applicant]
Office Action mailed Jul. 6, 2018, in U.S. Appl. No. 15/654,289, Peters, K., et al., filed Jul. 19, 2017, 8 pages.
[cited by applicant]
Office Action mailed Jul. 9, 2018, in U.S. Appl. No. 15/463,340, Peters, K., et al., filed Mar. 20, 2017, 14 pages.
[cited by applicant]
Office Action mailed Mar. 1, 2018, in U.S. Appl. No. 15/438,218, Peters, K., et al., filed Feb. 21, 2017, 10 pages.
[cited by applicant]
Office Action mailed May 15, 2014, in U.S. Appl. No. 13/652,203, Peters, K., et al., filed Oct. 15, 2012, 12 pages.
[cited by applicant]
Office Action mailed Sep. 11, 2013, in U.S. Appl. No. 13/652,203, Peters, K., et al., filed Oct. 15, 2012, 10 pages.
[cited by applicant]
Office Action mailed Sep. 22, 2016, in U.S. Appl. No. 14/627,463, Peters, K., et al., filed Feb. 20, 2015, 24 pages.
[cited by applicant]
Office Action mailed Sep. 5, 2013, in U.S. Appl. No. 13/652,154, Peters, K., et al., filed Oct. 15, 2012, 23 pages.
[cited by applicant]
Oliner, J., et al., “Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2,” Cancer Cell. 6(5):507-516, Cell Press, United States (Nov. 2004).
[cited by applicant]
Park, Y-H., et al., “Effect of sorafenib on experimental choroidal neovascularization in the rat,” Clin Experiment Ophthalmol. 38(7):718-726, Royal Australian and New Zealand College of Ophthalmologists, Australia (Oct.…
[cited by applicant]
Praidou, A., et al., “Angiogenic growth factors and their inhibitors in diabetic retinopathy,” Curr Diabetes Rev. 6(5):304-312, Bentham Science Publishers Ltd., United Arab Emirates (Sep. 2010).
[cited by applicant]
Riemer, A.B., et al., Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu—a new method of epitope definition. Mol Immunol. 42(9):1121-1124, Elsevier, Netherlands (May 2005).
[cited by applicant]
Saharinen, P., et al., “Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts,” Nat Cell Biol. 10(5):527-537, Supplementary Information, Nature Publishing Group, Ger…
[cited by applicant]
Schindelholz, B, et al., “Regulation of CNS and motor axon guidance in
[cited by applicant]
Shen J, et al., “In Vivo Immunostaining Demonstrates Macrophages Associate with Growing and Regressing Vessels,” Invest. Ophthalmol. Vis. Sci., 48(9):4335-4341, Association for Research in Vision and Ophthalmology, Unit…
[cited by applicant]
Sidwell, R.W., et al. “Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice,” Antimicrob Agents Chemother. 36(2):473-476, American Society for Microbiology…
[cited by applicant]
Smith, L. E. H., et al., “Oxygen-induced retinopathy in the mouse,” Invest Ophthalmol Vis Sci. 35(1):101-111, Association for Research in Vision and Ophthalmology (Jan. 1994).
[cited by applicant]
Sone, H., et al., “Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy,” Life Sci. 65(24):2573-2580, Else…
[cited by applicant]
Stancovski, I., et al., “Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth,” Proc Natl Acad Sci U SA. 88(19):8691-8695, United States National Academy of Sciences…
[cited by applicant]
Supplementary European Search Report and Search Opinion for EP Application No. EP 12840220.3, Munich, Germany, mailed on May 11, 2015, 7 pages.
[cited by applicant]
Supplementary European Search Report and Search Opinion for EP Application No. EP 12840725.1, Munich, Germany, mailed on May 12, 2015.
[cited by applicant]
Tobe, T., et al., “Targeted Disruption of the FGF2 Gene Does Not Prevent Choroidal Neovascularization in a Murine Model,” Am. J. Pathol., 153(5):1641-1646, American Society to Investigative Pathology (1998).
[cited by applicant]
Varughese, M., et al., “Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies,” Mol Med. 4(2):87-95, Springer Nature, Germany (Feb. 1998).
[cited by applicant]
Yacyshyn, O.K., et al., “Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells,” Angiogenesis 12(1):25-33 Springer Science+Business Media B.V., Germany (2009).
[cited by applicant]
Office Action mailed Sep. 16, 2022, in U.S. Appl. No. 16/784,970, Rotello, R.J., et al., filed Feb. 7, 2020, 18 pages.
[cited by applicant]
Office Action mailed Nov. 29, 2022, in U.S. Appl. No. 16/751,824, Peters, K., et al., filed Jan. 24, 2020, 21 pages.
[cited by applicant]
Office Action mailed Dec. 14, 2022, in U.S. Appl. No. 17/027,034, Peters, K., et al., filed Sep. 21, 2020, 11 pages.
[cited by applicant]
Saharinen, P., et al., “Therapeutic targeting of the angiopoietin-TIE pathway,” Nat Rev Drug Discov 16(9):635-661, Nature Portfolio, Germany (Sep. 2017).
[cited by applicant]
Souma, T., et al., “Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP,” Proc Natl Acad Sci USA 115(6):1298-1303, National Academy of Sciences, United States (Feb. 2018).
[cited by applicant]
U.S. Appl. No. 18/443,782, filed Feb. 16, 2024, Inventors: Kevin Peters et al., Applicant: EyePoint Pharmaceuticals, Inc.
[cited by applicant]
Campochiaro, P., et al., “Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema,” Current Diabetes Reports 16(12):126, Springer Nature, United States (Dec. 2016).
[cited by applicant]
Kim, J., et al., “Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma,” The Journal of Clinical Investigation 127(10):3877-3896, American Society for Clinical Investigation, U…
[cited by applicant]
Takagi, H., et al., “Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization,” Investigative Ophthalmology & Visual Science 44(1):393-402, Association for Research in Vision and Oph…
[cited by applicant]
Campochiaro, P., et al., “Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2,” Ophthalmology 122(3):545-554, Elsevier, United States (Mar. 2015…
[cited by applicant]
Brigell, M., et al., “A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses o…
[cited by applicant]
Shen, J., et al., “Blockade of Vascular Endothelial Protein Tyrosine Phosphatase: A Novel Approach to Stabilizing the Retinal Vasculature,” Investigative Ophthalmology & Visual Science.
[cited by applicant]
(ARVO Annual Meeting Abstract) 54(15): 6094, 1 page, Association for Research in Vision and Ophthalmology, United States (Jun. 2013).
[cited by applicant]